LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

22.99 -1.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

22.41

Max

23.92

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+78.86% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	143M 1.6B
Vorige openingsprijs	24.78
Vorige sluitingsprijs	22.99

Nieuwssentiment

By Acuity

50%

155 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 feb 2026, 16:32 UTC

Winsten

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13 feb 2026, 21:57 UTC

Winsten

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Winsten

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Marktinformatie

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Marktinformatie

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Marktinformatie

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Marktinformatie

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Winsten

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Acquisities, Fusies, Overnames

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 feb 2026, 17:52 UTC

Winsten

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 feb 2026, 17:16 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 17:10 UTC

Acquisities, Fusies, Overnames

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 feb 2026, 16:59 UTC

Winsten

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 feb 2026, 16:39 UTC

Acquisities, Fusies, Overnames

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 feb 2026, 16:11 UTC

Winsten

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 feb 2026, 16:07 UTC

Marktinformatie

Hungarian Forint Could Rise Further -- Market Talk

13 feb 2026, 15:54 UTC

Winsten

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 feb 2026, 15:26 UTC

Marktinformatie

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 feb 2026, 15:01 UTC

Winsten

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 feb 2026, 15:00 UTC

Winsten

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 feb 2026, 14:50 UTC

Marktinformatie

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 feb 2026, 14:44 UTC

Winsten

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 feb 2026, 14:22 UTC

Marktinformatie

Winsten

Global Energy Roundup: Market Talk

13 feb 2026, 14:21 UTC

Marktinformatie

Winsten

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13 feb 2026, 14:13 UTC

Marktinformatie

U.S. Natural Gas Futures Move Lower -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

78.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44 USD 78.86%

Hoogste 62 USD

Laagste 24 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

155 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.